Seralutinib
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension[1][2].
Product Specifications
CAS Number
1619931-27-9
Product Name Alternative
GB002; PK10571
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Fms; c-Kit; PDGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/seralutinib.html
Concentration
10mM
Purity
99.94
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C)=CN=C1)NC2=CC=CC([C@@H](NC3=NC(C4=CC=C(OC)C(OC)=C4)=CN=C3)C)=C2
Molecular Formula
C27H27N5O3
Molecular Weight
469.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Anna Galkin, et al. Abstract 11102: Gb002, A Novel Inhaled Pdgfr Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah) . Circulation. 2019;140:A11102.|[2]Anna Galkin, et al. Pharmacologic Characterization of GB002, a Novel Inhaled PDGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH) .|[3]Robert P. Frantz1, et.al. Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 (Seralutinib) for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PDGFRα; PDGFRβ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
